| Cat.No. | Name | Information |
|---|---|---|
| M1962 | Lenalidomide | Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties. |
| M55907 | Semapimod tetrahydrochloride | Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. |
| M53365 | Epobis | Epobis, a dendrimeric peptide, is a recombinant form of erythropoietin. Epobis is a potent erythropoietin receptor agonist. Epobis promotes neuritogenesis in primary motoneurons. |
| M49437 | Afimkibart | Afimkibart (PF-06480605) is an IgG1 human monoclonal antibody against TNF-like ligand 1A (TL1A, TNFSF15), which can be used in studies related to ulcerative colitis (UC). |
| M45266 | Linvoseltamab | Linvoseltamab is a bispecific antibody targeting BCMA (TNFRSF17) and CD3. Linvoseltamab is used in studies related to relapsed/refractory multiple myeloma (R/R MM). |
| M40592 | Certolizumab | Certolizumab is a recombinant, polyethylene glycolated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor (TNF)-alpha, and may be used in psoriasis-related studies. |
| M31423 | SAR-441566 | SAR-441566 is an orally active TNF-α inhibitor that blocks the interaction of TNFα with TNFR1 by distorting the conformation of the soluble TNFα trimer and does not affect signaling of TNFα bound to cell membranes, and can be used in rheumatoid arthritis-related studies. |
| M25496 | DRI-C21045 | DRI-C21045 is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 µM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC50s of 17.1 µM and 4.5 µM, respectively. |
| M25227 | Golimumab | Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research. |
| M25217 | Belimumab | Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. |
| M25161 | Rocatinlimab | Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD). |
| M24932 | Ivuxolimab | Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4+ and CD8+ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity. |
| M24931 | Telazorlimab | Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases. |
| M24928 | Teclistamab | Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM). |
| M24906 | Brentuximab | Brentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies. |
| M24893 | Mitazalimab | Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment. |
| M24765 | Vonlerolizumab | Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal OX40-specific antibody. Vonlerolizumab can be used for the research of cancer. |
| M18028 | 8-Epi-Loganic acid-6'-O-β-D-glucoside | 8-Epi-Loganic acid-6'-O-β-D-glucoside |
| M13561 | C25-140 | C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity. |
| M13560 | AX-024 | AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
